The antipsychotic effects of ECT: A review of possible mechanisms

Journal of ECT

Volumn 30, Issue 2, 2014, Pages 125-131

  Rosenquist, Peter B ^a   Miller, Brian ^a   Pillai, Anilkumar ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Antipsychotic drugs; Brain derived neurotrophic factor; Cytokines; ECT; Mechanism of action

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CHLORPROMAZINE; CLOZAPINE; CORTICOSTEROID; DOPAMINE; DOPAMINE RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NERVE GROWTH FACTOR; NEUROLEPTIC AGENT; NEUROTROPHIN; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PHENCYCLIDINE; PSYCHEDELIC AGENT; PSYCHOSTIMULANT AGENT; QUETIAPINE; SEROTONIN; SEROTONIN RECEPTOR;

AUTOIMMUNITY; CEREBROSPINAL FLUID; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DEPRESSIVE PSYCHOSIS; DRUG EFFICACY; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; HIPPOCAMPUS; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INFLAMMATION; MENTAL PATIENT; MONOTHERAPY; MOOD DISORDER; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SYMPTOM; THERAPY EFFECT; ANIMAL; METABOLISM; MOOD DISORDERS; PROCEDURES; PSYCHOTIC DISORDERS;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE; ELECTROCONVULSIVE THERAPY; HUMANS; MOOD DISORDERS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEROTONIN;

EID: 84901591013     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0000000000000131     Document Type: Review

References (89)

1. Leiknes KA, Jarosh-von SL, Hoie B. Contemporary use and practice of electroconvulsive therapy worldwide. Brain Behav. 2012;2:283-344.
2. Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: A report from CORE. J ECT. 2001;17:244-253. (Pubitemid 33131305)
3. Wijkstra J, Lijmer J, Balk FJ, et al. Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Br J Psychiatry. 2006;188:410-415.
4. Haskett RF, Rosenquist PB, McCall WV, et al. The role of antidepressant medications during ECT: new findings from OPT-ECT. J ECT. 2007;23:56.
5. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: A randomized controlled trial. JAMA. 2001;285:1299-1307. (Pubitemid 32216144)
6. Dinwiddie SH, Drevets WC, Smith DR. Treatment of phencyclidine-associated psychosis with ECT. Convuls Ther. 1988;4:230-235.
7. Rosen AM, Mukherjee S, Shinbach K. The efficacy of ECT in phencyclidine-induced psychosis. J Clin Psychiatry. 1984;45:220-222. (Pubitemid 14107399)
8. Grelotti DJ, Kanayama G, Pope HG Jr. Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy: presentation of a case and review of the literature. Am J Psychiatry. 2010;167:17-23.
9. Friedman JH. Parkinson disease psychosis: update. Behav Neurol. 2013;27:469-477.
10. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: A double-blind labeled study of 3 months'duration. Mov Disord. 2007;22:313-318. (Pubitemid 46569682)
11. ChanpattanaW, Chakrabhand ML, Kongsakon R, et al. Short-term effect of combined ECT and neuroleptic therapy in treatment-resistant schizophrenia. J ECT. 1999;15:129-139. (Pubitemid 30012229)
12. Braga RJ, Petrides G. The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. J ECT. 2005;21:75-83. (Pubitemid 40800031)
13. Masoudzadeh A, Khalilian AR. Comparative study of clozapine, electroshock and the combination of ECT with clozapine in treatment-resistant schizophrenic patients. Pak J Biol Sci. 2007;10:4287-4290. (Pubitemid 350158596)
14. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry. 1978;135:165-173.
15. Tost H, Alam T, Meyer-Lindenberg A. Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes. Neurosci Biobehav Rev. 2010;34:689-700.
16. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011;11:59-67.
17. Smith SE, Acton L, Sharp T. Enhancement of dopamine-mediated behaviour by the NMDA antagonists MK-801 and CPP: similarities with repeated electroconvulsive shock. Psychopharmacology (Berl). 1997;133:85-94. (Pubitemid 27395824)
18. Zarrindast MR, Sahebgharani M, Burnham WM. The effect of electroconvulsive shock seizures on behaviour induced by dopaminergic agonists and on immobility in the Porsolt test. Eur Neuropsychopharmacol. 2004;14:509-514. (Pubitemid 39626900)
19. Stenfors C, Bjellerup P, Mathe AA, et al. Concurrent analysis of neuropeptides and biogenic amines in brain tissue of rats treated with electroconvulsive stimuli. Brain Res. 1995;698:39-45.
20. West CH, Weiss JM. Effects of chronic antidepressant drug administration and electroconvulsive shock on activity of dopaminergic neurons in the ventral tegmentum. I. Int J Neuropsychopharmacol. 2011;14:201-210.
21. Chao YL, Chen HH, Chen CH. Effects of repeated electroconvulsive shock on methamphetamine-induced behavioral abnormalities in mice. Brain Stimul. 2012;5:393-401.
22. Scheepers FE, Gispen-de Wied CC, Westenberg HG, et al. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology. 2001;25:468-475. (Pubitemid 32830951)
23. Rudorfer MV, Risby ED, Osman OT, et al. Hypothalamic-pituitary-adrenal axis and monoamine transmitter activity in depression: A pilot study of central and peripheral effects of electroconvulsive therapy. Biol Psychiatry. 1991;29:253-264.
24. Nikisch G, Mathe AA. CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy. Eur Psychiatry. 2008;23:356-359.
25. Cooper SJ, Leahey W, Green DF, et al. The effect of electroconvulsive therapy on CSF amine metabolites in schizophrenic patients. Br J Psychiatry. 1988;152:59-63. (Pubitemid 18047609)
26. Ito M, Hatta K, Usui C, et al. Urine catecholamine levels are not influenced by electroconvulsive therapy in depression or schizophrenia over the long term. Psychiatry Clin Neurosci. 2012;66:602-610.
27. West CH, Weiss JM. Effects of chronic antidepressant drug administration and electroconvulsive shock on activity of dopaminergic neurons in the ventral tegmentum. Int J Neuropsychopharmacol. 2011;14:201-210.
28. Wode-Helgodt B, Fyro B, Gullberg B, et al. Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients. Acta Psychiatr Scand. 1977;56:129-142. (Pubitemid 8160021)
29. Harnryd C, Bjerkenstedt L, Grimm VE, et al. Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment. Psychopharmacology (Berl.). 1979;64:131-134. (Pubitemid 9251061)
30. Yatham LN, Liddle PF, Lam RW, et al. Effect of electroconvulsive therapy on brain 5-HT(2) receptors in major depression. Br J Psychiatry. 2010;196:474-479.
31. Saijo T, Takano A, Suhara T, et al. Effect of electroconvulsive therapy on 5HT-1A receptor binding in patients with depression: A PET study with [11C]WAY 100635. Int J Neuropsycholopharmacol. 2010:13:785-791.
32. Lanzenberger R, Baldinger P, Hahn A, et al. Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. Mol Psychiatry.2013; 18: 93-100.
33. McCormick LM, Boles Ponto LL, Pierson RK, et al. Metabolic correlates of antidepressant and antipsychotic response in aptients with psychotic depression undergoing electroconvulsive therapy. J ECT. 2007;23:265-273. (Pubitemid 350307767)
34. Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull. 2009;35:528-548.
35. Pillai A. Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia. Neurosignals. 2008;16:183-193. (Pubitemid 351263224)
36. Issa G, Wilson C, Terry AV Jr, et al. An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies. Neurobiol Dis. 2010;39:327-333.
37. Pandya CD, Kutiyanawalla A, Pillai A. BDNF-TrkB signaling and neuroprotection in schizophrenia. Asian J Psychiatr. 2013;6:22-28.
38. Pillai A, Terry AV Jr, Mahadik SP. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res. 2006;82:95-106. (Pubitemid 43202652)
39. Newton SS, Collier EF, Hunsberger J, et al. Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J Neurosci. 2003;23:10841-10851. (Pubitemid 37499691)
40. Madsen TM, Treschow A, Bengzon J, et al. Increased neurogenesis in a model of electroconvulsive therapy. Biol Psychiatry. 2000;47:1043-1049. (Pubitemid 30336212)
41. Zhao C, Warner-Schmidt J, Duman RS, et al. Electroconvulsive seizure promotes spine maturation in newborn dentate granule cells in adult rat. Dev Neurobiol. 2012;72:937-942.
42. Martinotti G, Ricci V, Di Nicola M, et al. Brain-derived neurotrophic factor and electroconvulsive therapy in a schizophrenic patient with treatment-resistant paranoid-hallucinatory symptoms. J ECT. 2011;27:e44-e46.
43. Fernandes BS, Massuda R, Torres M, et al. Improvement of schizophrenia with electroconvulsive therapy and serum brain-derived neurotrophic factor levels: lack of association in a pilot study. Psychiatry Clin Neurosci. 2010;64:663-665.
44. Bocchio-Chiavetto L, Zanardini R, et al. Electroconvulsive therapy (ECT) increases serum brain derived neurotrophic factor (BDNF) in drug resistant depressed patients. Eur Neuropsychopharmacol. 2006;16:620-624. (Pubitemid 44781079)
45. Hu Y, Yu X, Yang F, et al. The level of serum brain-derived neurotrophic factor is associated with the therapeutic efficacy of modified electroconvulsive therapy in Chinese patients with depression. J ECT. 2010;26:121-125.
46. Grønli O, Stensland GØ, Wynn R, et al. Neurotrophic factors in serum following ECT: A pilot study. World J Biol Psychiatry. 2009;10:295-301.
47. Fernandes B, Gama CS, Massuda R, et al. Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): A pilot study in drug resistant depressed patients. Neurosci Lett. 2009;453:195-198.
48. Skaper SD, Floreani M, Negro A, et al. Neurotrophins rescue cerebellar granule neurons from oxidative stress-mediated apoptotic death: selective involvement of phosphatidylinositol 3-kinase and the mitogen-activated protein kinase pathway. J Neurochem. 1998;70:1859-1868. (Pubitemid 28207807)
49. Mahadik SP, Pillai A, Joshi S, et al. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int Rev Psychiatry. 2006;18:119-131. (Pubitemid 43791675)
50. Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress inschizophrenia. Biol Psychiatry. 2013; 74:400-409.
51. Kartalci S, Karabulut AB, Ozcan AC, et al. Acute and chronic effects of electroconvulsive treatment on oxidative parameters in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1689-1694.
52. Hsu PC, Nwulia E, Sawa A. Using bioinformatic tools. Am J Psychiatry. 2009;166:854.
53. International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748-752.
54. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: A review of epidemiological and translational studies. Am J Psychiatry. 2010;167:261-280.
55. Eaton WW, Byrne M, Ewald H, et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry. 2006;163:521-528. (Pubitemid 44469397)
56. Benros ME, Nielsen PR, Nordentoft M, et al. Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study. Am J Psychiatry. 2011; 168:1303-1310.
57. Miller B, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:663-671.
58. Miller BJ, Culpepper N, Rapaport MH. C-Reactive Protein in Schizophrenia: A Review and Meta-Analysis. Clin Schizophr Relat Psychoses. 2014;7:223-230.
59. Miller B, Gassama B, Sebastian D, et al. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2013;73:993-999.
60. Ezeoke A, Mellor A, Buckley P, et al. A systematic quantitative review of blood autoantibody elevations in schizophrenia. Schizophr Res. 2013;150:245-251.
61. Nikkilä H, Müller K, Ahokas A, et al. Abnormal distributions of T-lymphocyte subsets in the cerebrospinal fluid of patients with acute schizophrenia. Schizophr Res. 1995;14:215-221.
62. Nikkilä HV, Müller K, Ahokas A, et al. Accumulation of macrophages in the CSF of schizophrenic patients. Am J Psychiatry. 1999;156: 1725-1729. (Pubitemid 29517564)
63. Garver DL, Tamas RL, Holcomb JA. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacol. 2003;28:1515-1520. (Pubitemid 41070887)
64. Sasayama D, Hattori K, Wakabayashi C, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res. 2013;47:401-406.
65. Doorduin J, de Vries EF, Willemsen AT, et al. Neuroinflammation in schizophrenia-related psychosis: A PET study. J Nucl Med. 2009;50:1801-1807.
66. Nitta M, Kishimoto T, Müller N, et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials. Schizophr Bull. 2013;39:1230-1241.
67. Miller BJ, Buckley P. Is relapse in schizophrenia an immune-mediated effect? FOCUS: The Journal of Lifelong Learning in Psychiatry. 2012;10:115-123.
68. Modabbernia A, Taslimi S, Brietzke E, et al. Cytokine alterations in bipolar disorder: A meta-analysis of 30 studies. Biol Psychiatry. 2013;74:15-25.
69. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446-457.
70. Fond G, Hamdani N, Kapczinski F, et al. Effectiveness and tolerance of anti-inflammatory drugs'add-on therapy in major mental disorders: A systematic qualitative review. Acta Psychiatr Scand. 2013; Nov 11. doi: 10.1111/acps.12211.
71. Sommer IE, van Westrhenen R, Begemann MJ, et al. Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update. Schizophr Bull. 2014;40:181-191.
72. Fluitman SB, Heijnen CJ, Denys DA, et al. Electroconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder. J Affect Disord. 2011;131:388-392.
73. Chaturvedi S, Chadda RK, Rusia U, et al. Effect of electroconvulsive therapy on hematological parameters. Psychiatry Res. 2001;102: 265-268. (Pubitemid 33135508)
74. Prior T, Chue P. Psychotic depression occurring after stopping interferon-alpha. J Clin Psychopharmacol. 1999;19:385-386.
75. Zincke MT, Kurani A, Istafanous R, et al. The successful use of electroconvulsive therapy in a patient with interferon-induced psychotic depression. J ECT. 2007;23:291-292. (Pubitemid 350307774)
76. Ohaeri JU, Hedo CC, Lagundoye OO. The profile of C-reactive proteins in functional psychotic states in a cohort in Nigeria. Acta Psychiatr Scand. 1993;88:252-255. (Pubitemid 23305181)
77. Albrecht J, Helderman JH, Schlesser MA, et al. A controlled study of cellular immune function in affective disorders before and during somatic therapy. Psychiatry Res. 1985;15:185-193. (Pubitemid 15042330)
78. Fischler B, Bocken R, Schneider I, et al. Immune changes induced by electroconvulsive therapy (ECT). Ann N Y Acad Sci. 1992;650:326-330.
79. Kronfol Z, Nair MP,Weinberg V, et al. Acute effects of electroconvulsive therapy on lymphocyte natural killer cell activity in patients with major depression. J Affect Disord. 2002;71:211-215.
80. Kronfol Z, Lemay L, Nair M, et al. Electroconvulsive therapy increases plasma levels of interleukin-6. Ann NY Acad Sci. 594, 463-465.
81. Lehtimäki K, Keränen T, Huuhka M, et al. Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder. J ECT. 2008; 24: 88-91. (Pubitemid 351498648)
82. Giltay EJ, Kho KH, Blansjaar BA. Serum markers of brain-cell damage and C-reactive protein are unaffected by electroconvulsive therapy. World J Biol Psychiatry. 2008;9:231-235.
83. Hestad KA, Tønseth S, Støen CD, et al. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT. 2003;19:183-188. (Pubitemid 38018294)
84. Rotter A, Biermann T, Stark C, et al. Changes of cytokine profiles during electroconvulsive therapy in patients with major depression. J ECT. 2013;29:162-169.
85. Bocchio-Chiavetto L, Zanardini R, Bortolomasi M, et al. Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. Eur Neuropsychopharmacol. 2006;16:620-624. (Pubitemid 44781079)
86. Minelli A, Zanardini R, Abate M, et al. Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1322-1325.
87. Piccinni A, Del Debbio A, Medda P, et al. Plasma Brain-Derived Neurotrophic Factor in treatment-resistant depressed patients receiving electroconvulsive therapy. Eur Neuropsychopharmacol. 2009;19:349-355.
88. Di Nicola M, Cattaneo A, Hepgul N, et al. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav Immun. 2013;31:90-95.
89. Green MJ, Matheson SL, Shepherd A, et al. Brain-derived neurotrophic factor levels in schizophrenia: A systematic review with meta-analysis. Mol Psychiatry. 2011;16:960-972.